Norman Ng, Director of Patient Advocacy and Public Affairs of Healthcare Thinkers, shared a post on LinkedIn:
“Accelerated approval, flexible and efficient, bringing new hope to patients!
In the past, the approval of a phase of a clinical trial in Hong Kong generally took six to nine months or even longer. The first phase of clinical research led by CUH University not only won the full approval of the Department of Health and the Ethics Committee, but also quickly recruited the first batch of Chinese patients in the world. The time required was significantly shorter than in the past, and the clinical implementation was more fruitful.
This innovative therapy for colorectal cancer, pancreatic cancer and lung cancer is expected to bring new light to patients with complex conditions and lack standard treatment plans, help improve the overall quality of medical care, and keep the clinical pace of drug development in sync with the international market.”
More posts featuring Norman Ng on OncoDaily.